lung adenocarcinoma (Cancer)
Information
- Disease name
- lung adenocarcinoma
- Disease ID
- DOID:3910
- Description
- "A lung non-small cell carcinoma that derives_from epithelial cells of glandular origin." [url:http\://cancergenome.nih.gov/cancersselected/lungadenocarcinoma, url:http\://en.wikipedia.org/wiki/Adenocarcinoma, url:http\://en.wikipedia.org/wiki/Adenocarcinoma_of_the_lung]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| EGFR | 7 | 55,019,017 | 55,211,628 | 32 |
| TP53 | 17 | 7,668,421 | 7,687,490 | 26 |
| ATRX | X | 77,504,880 | 77,786,216 | 14 |
| ARID1A | 1 | 26,696,015 | 26,782,104 | 10 |
| ZFHX3 | 16 | 72,782,885 | 73,891,871 | 8 |
| TERT | 5 | 1,253,167 | 1,295,068 | 8 |
| EPHB1 | 3 | 134,795,260 | 135,260,467 | 8 |
| RB1 | 13 | 48,303,751 | 48,481,890 | 6 |
| SMAD4 | 18 | 51,030,209 | 51,085,042 | 6 |
| PIK3CA | 3 | 179,148,357 | 179,240,093 | 6 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00334815 | Active, not recruiting | Phase 2 | Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | June 15, 2006 | February 22, 2025 |
| NCT01386385 | Active, not recruiting | Phase 1/Phase 2 | Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | June 20, 2011 | December 31, 2024 |
| NCT02186847 | Active, not recruiting | Phase 2 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | August 2014 | April 16, 2025 |
| NCT04740047 | Active, not recruiting | Cios Mobile 3D Spin for Robotic Bronchoscopy | February 1, 2021 | May 2024 | |
| NCT03054298 | Active, not recruiting | Phase 1 | CAR T Cells in Mesothelin Expressing Cancers | April 6, 2017 | March 2025 |
| NCT05982574 | Active, not recruiting | Tumor Microenvironment | February 2016 | December 2026 | |
| NCT01737502 | Completed | Phase 1/Phase 2 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | May 14, 2014 | April 24, 2023 |
| NCT02980991 | Completed | Phase 2 | Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002) | December 2015 | April 2018 |
| NCT00716456 | Completed | Phase 1/Phase 2 | Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib | July 2008 | May 2011 |
| NCT00950365 | Completed | Phase 2 | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | April 2006 | November 17, 2017 |
| NCT00126581 | Completed | Phase 2 | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | August 15, 2005 | November 28, 2017 |
| NCT01294306 | Completed | Phase 2 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | February 2011 | August 2015 |
| NCT01578668 | Completed | Phase 2 | Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases | January 2012 | January 2015 |
| NCT02679443 | Completed | N/A | Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy | July 2015 | December 2016 |
| NCT03544814 | Completed | Phase 2 | EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression | January 1, 2015 | December 30, 2017 |
| NCT03076164 | Completed | Phase 1/Phase 2 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | March 1, 2017 | December 18, 2020 |
| NCT02759835 | Completed | Phase 2 | Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | April 13, 2016 | September 20, 2022 |
| NCT04893200 | Completed | Radiomics-based Prediction Model of Tumor Spread Through Air Space in Lung Adenocarcinoma | February 1, 2020 | June 1, 2021 | |
| NCT02093000 | Completed | A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma | November 30, 2014 | January 31, 2018 | |
| NCT02127359 | Completed | Whole-Exome Sequencing (WES) of Cancer Patients | September 2012 | December 2019 | |
| NCT03922828 | Completed | Lung Nodule Prospective Database | May 1, 2018 | January 1, 2021 | |
| NCT03904563 | Completed | Phase 2 | Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma | January 1, 2019 | December 15, 2022 |
| NCT03704870 | Completed | Phase 2 | Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection | January 26, 2018 | March 31, 2020 |
| NCT04965831 | Not yet recruiting | Phase 2 | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) | August 1, 2021 | May 1, 2026 |
| NCT06104709 | Not yet recruiting | Local and Peripheral Immune Responsive Landscape Induced by Local Cryoablation in Patients With Lung Adenocarcinoma | December 1, 2023 | December 31, 2024 | |
| NCT05675033 | Not yet recruiting | Phase 2 | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | January 10, 2023 | January 10, 2024 |
| NCT05279521 | Not yet recruiting | N/A | The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer. | March 20, 2022 | December 30, 2024 |
| NCT06255197 | Recruiting | Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers | November 4, 2019 | December 31, 2031 | |
| NCT03199651 | Recruiting | N/A | Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer | July 17, 2017 | December 31, 2027 |
| NCT03391869 | Recruiting | Phase 3 | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | December 29, 2017 | December 31, 2025 |
| NCT04119024 | Recruiting | Phase 1 | Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | November 27, 2019 | October 1, 2025 |
| NCT04339218 | Recruiting | Phase 3 | Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma | August 28, 2020 | August 2025 |
| NCT04625647 | Recruiting | Phase 2 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | April 16, 2021 | December 31, 2027 |
| NCT04802876 | Recruiting | Phase 2 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors | April 12, 2021 | March 31, 2027 |
| NCT04929041 | Recruiting | Phase 2/Phase 3 | Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative | October 7, 2022 | December 31, 2027 |
| NCT04937283 | Recruiting | N/A | Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | October 1, 2019 | December 30, 2028 |
| NCT05191485 | Recruiting | Shared Decision Making in Patients With Lung Cancer | February 22, 2023 | December 2026 | |
| NCT05198830 | Recruiting | Phase 2 | Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | December 15, 2022 | December 31, 2025 |
| NCT05266846 | Recruiting | Phase 2 | Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK | May 29, 2024 | February 16, 2027 |
| NCT05395611 | Recruiting | Exhaled Breath Particles in Lung Cancer | January 23, 2018 | January 2025 | |
| NCT05498597 | Recruiting | Phase 1 | AMT-151 in Patients With Selected Advanced Solid Tumours | January 25, 2023 | October 30, 2024 |
| NCT05517811 | Recruiting | Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection | June 1, 2022 | July 31, 2024 | |
| NCT05526573 | Recruiting | Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions | July 14, 2022 | December 31, 2025 | |
| NCT05527808 | Recruiting | N/A | A Single-arm Exploratory Study of Neoadjuvant Therapy | August 1, 2022 | December 30, 2025 |
| NCT05528458 | Recruiting | Phase 2 | Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma | July 26, 2022 | December 1, 2029 |
| NCT05537922 | Recruiting | I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy | October 1, 2022 | October 1, 2027 | |
| NCT05558904 | Recruiting | Phase 1/Phase 2 | An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer | January 19, 2023 | October 1, 2026 |
| NCT05717803 | Recruiting | Phase 3 | Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) | February 15, 2023 | December 31, 2029 |
| NCT05736991 | Recruiting | Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma | November 1, 2022 | April 30, 2023 | |
| NCT05794698 | Recruiting | Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1014) | January 1, 2022 | December 31, 2024 | |
| NCT05794711 | Recruiting | Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015) | January 1, 2022 | December 31, 2024 | |
| NCT05794724 | Recruiting | Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016) | January 1, 2022 | December 31, 2023 | |
| NCT05797168 | Recruiting | Phase 1/Phase 2 | Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors | June 5, 2023 | November 1, 2027 |
| NCT05838053 | Recruiting | Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | August 20, 2019 | April 30, 2028 | |
| NCT05925764 | Recruiting | Whole Slide Image for Predicting the Novel Grading System of Resected Lung Adenocarcinoma | May 1, 2023 | October 31, 2023 | |
| NCT06031181 | Recruiting | Phase 3 | Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019) | March 31, 2023 | December 31, 2030 |
| NCT06031246 | Recruiting | Phase 3 | Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018) | April 1, 2023 | December 31, 2030 |
| NCT06056115 | Recruiting | N/A | Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic | May 1, 2023 | December 12, 2026 |
| NCT06181812 | Recruiting | Pathogenic Variants in Genes Associated With Lung Adenocarcinoma | December 15, 2022 | December 15, 2025 | |
| NCT02621333 | Terminated | Phase 2 | Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma | October 2015 | September 2018 |
| NCT03891173 | Terminated | Phase 2 | A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma | February 19, 2019 | May 22, 2020 |
| NCT00955305 | Terminated | Phase 2 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | March 2010 | November 2016 |
| NCT05012397 | Terminated | Phase 2 | Milademetan in Advanced/Metastatic Solid Tumors | November 1, 2021 | October 15, 2023 |
| NCT04682431 | Terminated | Phase 1 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | November 10, 2020 | August 31, 2023 |
| NCT04691375 | Terminated | Phase 1 | A Study of PY314 in Subjects With Advanced Solid Tumors | October 29, 2020 | September 22, 2023 |
| NCT02121925 | Terminated | Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up | May 2014 | July 31, 2017 | |
| NCT01578551 | Terminated | Phase 2 | Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. | May 2012 | January 2017 |
| NCT04861948 | Terminated | Phase 1 | IBI188 Combination Therapy in Solid Tumors | May 25, 2021 | July 30, 2022 |
| NCT02737774 | Unknown status | Phase 2 | Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation | April 13, 2016 | June 1, 2021 |
| NCT03376737 | Unknown status | Phase 2 | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma | October 12, 2017 | June 2019 |
| NCT05136014 | Unknown status | Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model | November 1, 2021 | November 1, 2022 | |
| NCT03486496 | Unknown status | Phase 2 | Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation | June 5, 2018 | February 1, 2020 |
| NCT02691871 | Unknown status | Phase 1 | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR | February 2016 | December 2016 |
| NCT02399566 | Unknown status | Phase 4 | Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma | May 2015 | January 2019 |
| NCT03905317 | Unknown status | Phase 2 | Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene | March 1, 2019 | February 2022 |
| NCT02282267 | Unknown status | N/A | Blood Detection of EGFR Mutation For Iressa Treatment | October 2014 | February 2018 |
| NCT01249053 | Unknown status | Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma | August 2010 | ||
| NCT04482829 | Unknown status | N/A | TCM in the Treatment of Lung Adenocarcinoma | September 15, 2020 | June 30, 2022 |
| NCT04554875 | Unknown status | Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules | January 1, 2019 | July 1, 2021 | |
| NCT04588064 | Unknown status | N/A | 18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma | July 1, 2020 | July 1, 2022 |
| NCT01249066 | Unknown status | Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma | September 2010 | ||
| NCT01482585 | Unknown status | Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy | October 2011 | December 2016 | |
| NCT01942629 | Unknown status | Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas | October 2013 | December 2015 | |
| NCT05010330 | Unknown status | Identify Prognostic Biomarkers of Lung Cancer | July 1, 2020 | September 30, 2021 | |
| NCT02788058 | Unknown status | Phase 2 | A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy | May 2016 | May 2022 |
| NCT02843711 | Unknown status | Molecular Analysis of 150 Lung Adenocarcinoma | January 2014 | December 2017 | |
| NCT02898857 | Unknown status | Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma | September 2016 | December 2017 | |
| NCT02951637 | Unknown status | Phase 2 | Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial | December 2016 | December 2019 |
| NCT02787447 | Unknown status | Phase 2 | Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | May 2016 | May 2020 |
| NCT02738684 | Unknown status | A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test | April 2016 | January 2018 | |
| NCT05400304 | Unknown status | Radiomics Combined With Frozen Section Prediction Model for Spread Through Air Space in Lung Adenocarcinoma | July 1, 2022 | May 12, 2023 | |
| NCT02011997 | Unknown status | Phase 3 | Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion | December 2013 | December 2021 |
| NCT04870034 | Withdrawn | Early Phase 1 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | January 15, 2024 | September 30, 2026 |
- Disase is a (Disease Ontology)
- DOID:3908
- Cross Reference ID (Disease Ontology)
- EFO:0000571
- Cross Reference ID (Disease Ontology)
- GARD:5742
- Cross Reference ID (Disease Ontology)
- MESH:D000077192
- Cross Reference ID (Disease Ontology)
- NCI:C27745
- Cross Reference ID (Disease Ontology)
- NCI:C3512
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:254626006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0152013
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1335060
- Exact Synonym (Disease Ontology)
- bronchogenic lung adenocarcinoma
- Exact Synonym (Disease Ontology)
- nonsmall cell adenocarcinoma
- Disase Synonym (Disease Ontology)
- adenocarcinoma of lung
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0030078